Skip to main content

Ervebo FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 29, 2020.

FDA Approved: Yes (First approved December 19, 2019)
Brand name: Ervebo
Generic name: ebola zaire vaccine, live
Previous name: rVSV∆G-ZEBOV-GP, live attenuated
Dosage form: Injection
Previous Name: V920
Company: Merck
Treatment for: Prevention of Ebola Zaire Disease

Ervebo (ebola zaire vaccine, live) is a vaccine indicated for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older.

Development timeline for Ervebo

Dec 19, 2019Approval FDA Approves Ervebo (Ebola Zaire Vaccine, Live) for the Prevention of Disease Caused by Zaire Ebolavirus
Sep 17, 2019FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus
Nov 13, 2018Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.